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S174 Oral Presentationsas well as regulatory T cells and are therefore of great interest for
post-transplant immunotherapy. Human B cells when activated via
CD40-L/IL-4 can be expanded from small amounts of peripheral
blood in 12-14 days. CD40-activated B cells can prime naı¨ve T cells,
expand memory T cells and express important surface homing mol-
ecules. Nevertheless, it remains unclear whether such cells have the
property to attract and interact withT cells in a physiological context
and whether CD40-activated B cells migrate to secondary lymphoid
organs (SLO) in vivo, a necessary step for an antigen-presenting cell
(APC) to induce immunity. To address this question we established
a platform to generate murine CD40-activated B cells. At day 14 of
culture, these cells are .95% CD19+ and CD80/86/MHCI/
MHCIIhi.Murine CD40-activated B cells present a ‘homing pheno-
type’; migrate towards SLO chemokines such as CCL19, CCL21
and CXCL13; and induce T-cell chemotaxis in vitro. Upon
CD40L activation, B cells up-regulate CCR7 while down-regulate
CXCR5 expression which suggests direction of activated B cells
towards the B-zone-T-zone boundary. We compared the homing
of GFP+ CD40-activated B cells to resting GFP+ B cells and
show for the first time that CD40-activated B cells home to SLO
significantly more efficiently than resting B cells. Furthermore,
CD40-activated B cells localize in B-cell areas, and a significant frac-
tion move to the B-T boundary close to the T-cell zone. To dissect
T-cell-APC interactions on a single cell we analyzed three-dimen-
sional migration in collagen matrix. Interestingly, antigen-loaded
CD40-activated B cells differ from immature andmature DC by dis-
playing a rapid migratory pattern undergoing highly dynamic, short-
lived (7.5 min) and sequential interactions with cognate T cells.
Taken together, these data reveal that CD40-activated B cells can
home to secondary lymphoid organs and interact dynamically with
T cells thus underlining their potential as cellular adjuvant for cancer
immunotherapy.53
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Viral infections causemorbidity andmortality in allogeneicHSCT
recipients. We and others have successfully generated and infused
adoptive T-cell lines specific for EBV, CMV and Adenovirus using
monocytes and EBV-transformed lymphoblastoid cell (EBV-LCL)
gene-modified with an adenovector as antigen presenting cells
(APCs). We have shown that as few as 2105/kg trivirus-specific
cytotoxic T lymphocytes (CTL) proliferated by several logs post-
infusion and appeared to prevent and treat even severe viral disease
resistant to other available therapies.Despite the encouraging clinical
results, broader implementation of this ‘‘trispecific’’ CTLapproach is
limited by high production costs, complexity of manufacture and the
prolonged time (4-6 weeks for EBV-LCL generation, and 6-8 weeks
for CTL manufacture – total 10-14 weeks) for preparation.
To overcome these manufacturing limitations we have developed
new, GMP-compliant strategies. In place of adenovectors we now
use DCs nucleofected with non-viral DNA plasmids encoding
LMP2 and BZLF1 (EBV), Hexon and Penton (Adv), pp65 (CMV)
and Large T antigen (BK virus) to stimulate T-cells. Furthermore,
by pooling nucleofected DCs prior to PBMC stimulation, we can
reproducibly generate multivirus-specific CTL lines reactive against
all the stimulating antigens, without discernible antigenic competi-
tion. Secondly, we have demonstrated that the culture of activated
T-cells in the presence of IL-4 (1,000U/ml) and IL-7 (10ng/ml) pro-
motes the survival of both high and low frequency antigen-specific
CTL and sustains the breadth of reactivity in our lines. Finally, we
have replaced traditional plastic cultureware with a new, gas perme-
able culture device (G-Rex) which promotes the expansion and
survival of large cell numbers in a closed systemwithminimal techni-
cian intervention. By implementing these changes we can now pro-
duce multispecific CTL targeting EBV, CMV, Ad, and BK virus at
a cost per 106 cells that is reduced by.90%, and in just 10 days rather
than 10 weeks using an approach that may be extended to additional
protective viral antigens. Our approach should be of value for pro-phylactic and treatment applications for high risk allogeneic HSCT
recipients.54
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Early immune reconstitution after allogeneic-haematopoietic
stem cell transplantation (HSCT) is important for controlling
infectious complications. We compared T-, B- and NK-cell recon-
stitution during the first 100 days after bone marrow (matched sib-
ling: id-SIB, unrelated bone marrow: u-BM) or cord blood (u-CB)
HSCT in a single-center prospective study among pediatric patients.
Between 2006 and 2008, 103 patients were included with a median
age of 5 years (range 0-21); 33 recipients received id-SIB, 33 u-BM
and 37 u-CB grafts. All patients received myelo-ablative condition-
ing and in the unrelated donor setting thymoglobulin (10 mg/kg)
was added from 4 to 2 days before SCT. The number of CD3+ cells
in the graft graft was for uCB 8*10e6 (range 8*10e5 – 4*10e7)/kg, for
id-SIB 4*10e7 (range 1 – 9*10e7)/kg and for u-BM 5 *10e7 (range
1*10e7 – 5*10e8)/kg.
Statistical analysis was performed by Kruskal-Wallis rank sum
tests and Wilcoxon tests with continuity corrections.
Median follow up was 16months (range 1-28); overall survival was
73%. Probability of neutrophil at day 60 did not differ among id-SIB
u-BM and u-CB recipients (median 23 days, range 3-60 after HSCT,
p5 0.092). Overall T-cell (CD3+) reconstitution (first 100 days) was
similar between the 3 groups, but CD8 +T-cell numbers were
higher after id-SIB- and u-BM compared to u-CB HSCT (155 and
309 versus 52 CD8 +T-cells/uL, p5 0.002). Interestingly, NK-
cell and B-cell numbers were significantly higher in u-CB compared
to id-SIB (p5 0.018 and p5 0.0003, resp.) and u-BM recipients
(p5 0.036 and p5 0.0003, resp.) within the first 100 days. On the
long term, in u-CB and id-SIB recipients higher ratios of nave
CD4+ and CD8 T-cells were found (u-CB: 62% and 87%, id-SIB:
55% and 57%) compared to u-BM recipients (30% and 17%) at
1 year after HSCT (p5 0.050 and p5 0.029).
Higher NK- and B-cell numbers early after HSCT indicate
a better proliferative capacity of these u-CB stem cells compared
to id-SIB and u-BM stem cells. We speculate the observed delayed
T-cell reconstitution after u-CB HSCT is caused by a deeper in
vivo depletion using the same dose of thymoglobuline in a setting
of u-CB grafting where the T-cell dose is 1 log lower than an u-BM
graft. Insight in the early immune reconstitution is essential for
the future development of immune-mediated therapies and the
development of optimal graft specific conditioning regimens to
prevent prolonged post-HSCT lymphopenia and the associated
viral complications.55
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Background: Respiratory virus infections cause significant morbid-
ity in stem cell transplant patients. Novel H1N1 Influenza A (Swine
Origin Influenza A, S-OIV) can result in severe disease in immuno-
compromised hosts.
Methods: Eleven hematopoietic stem cell transplant (HSCT) pa-
tients with influenza A were identified between 4/09 and 7/09.
This retrospective analysis summarizes the patient demographics,
clinical presentation, influenza testing, treatment, and outcome in
these S-OIV-infected HSCT recipients.
